Population Pharmacokinetics of L-AmB in Chinese Patients Assisted by Extracorporeal Membrane Pulmonary Oxygenation (ECMO)

Launched by BEIJING ANZHEN HOSPITAL · Dec 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called liposomal amphotericin B (L-AmB) works in patients with serious fungal infections who are receiving a special treatment called ECMO (Extracorporeal Membrane Oxygenation). ECMO is a life-support system that helps patients breathe when their lungs are not functioning properly. The researchers want to understand how L-AmB behaves in the body of patients using ECMO, which can help them determine the best way to administer the medication for effective treatment.

To participate in this trial, patients must be 18 years or older and diagnosed with a serious fungal infection while in the intensive care unit (ICU). They also need to be receiving ECMO assistance. However, individuals who cannot tolerate L-AmB, are pregnant, have a very limited life expectancy, or lack important health information will not be eligible. If you or a loved one qualifies, you can expect to be part of a study that aims to improve treatment strategies for critically ill patients with invasive fungal infections. The trial is not yet recruiting participants, but it will provide valuable insights into how to better use this medication in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnostic criteria for invasive fungal infections presenting to the intensive care unit (ICU) with probable or proved patients According to the 2021 EORTC/MSGERC guideline.
• • Requiring ECOM assistance.
• • Age 18 years.
• Exclusion Criteria:
• • Intolerance of L-AmB therapy.
• • Pregnancy.
• • Expected survival time \<24 hours.
• • Lack of necessary data on patient demographics physiopathology, and clinical status.